Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SurVaxM for Recurrent Glioblastoma
NCT04013672Phase 2Completed
- Start
- Mar 2020
- Primary completion
- Aug 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in glioblastoma (GBM). Started Mar 2020; status: completed.
02
Drugs
SurVaxM
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04013672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013672.